[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![wallstengine Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1508426880860704771.png) Wall St Engine [@wallstengine](/creator/twitter/wallstengine) on x 71.5K followers
Created: 2025-07-08 13:15:27 UTC

Novo Nordisk $NVO submits a new higher dose (7.2mg) of Wegovy to the EMA after trials showed XX% average weight loss, with a third of patients losing 25%+. Safety profile consistent with current 2.4mg dose. Another push by Novo Nordisk to expand its obesity treatment portfolio.


XXXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942573243388551403/c:line.svg)

**Related Topics**
[weight loss](/topic/weight-loss)
[wegovy](/topic/wegovy)
[$novcde](/topic/$novcde)
[$nvo](/topic/$nvo)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/wallstengine/status/1942573243388551403)